Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…
McAlinden Research PartnersJune 14, 2022
The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…
McAlinden Research PartnersDecember 22, 2021
